Arch Therapeutics, Inc.
ARTH · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $4,089 | $8,095 | $34,082 | $6,096 |
| - Cash | $30 | $26 | $206 | $223 |
| + Debt | $9,388 | $8,058 | $7,282 | $5,871 |
| Enterprise Value | $13,447 | $16,126 | $41,159 | $11,745 |
| Revenue | $31 | $32 | $46 | $40 |
| % Growth | -3% | -30.5% | 16.1% | – |
| Gross Profit | $10 | $10 | $22 | $16 |
| % Margin | 31.8% | 32.4% | 48.5% | 41.1% |
| EBITDA | -$4,982 | -$876 | -$1,494 | -$1,328 |
| % Margin | -16,117.4% | -2,749.6% | -3,257.3% | -3,361.3% |
| Net Income | -$5,655 | -$1,469 | -$2,682 | -$2,457 |
| % Margin | -18,292.2% | -4,610.4% | -5,846.6% | -6,218.1% |
| EPS Diluted | -1.44 | -0.33 | -0.57 | -0.52 |
| % Growth | -336.4% | 42.1% | -9.6% | – |
| Operating Cash Flow | -$912 | -$700 | -$863 | -$1,227 |
| Capital Expenditures | $0 | $0 | $0 | -$5 |
| Free Cash Flow | -$912 | -$700 | -$863 | -$1,231 |